Ethosuximide is used mainly in the treatment of petit mal epilepsy. However, it is also useful in akinetic and myoclonic attacks associated with generalised EEG spike-and-wave paroxysms.
Occasionally it is necessary to use a combination of sodium valproate and ethosuximide to control complex absences. This combination may also be used in patients with combined absence and tonic-clonic seizures where valproate may fail to satisfactorily control the absences.
The peak serum levels of ethosuximide occur 1-4 hours after administration and the control of absence seizures is highly correlated with plasma levels.
The summary of product characteristics should be consulted before prescribing this drug.
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page